1. Home
  2. BRIA vs VRCA Comparison

BRIA vs VRCA Comparison

Compare BRIA & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BRIA
  • VRCA
  • Stock Information
  • Founded
  • BRIA 2011
  • VRCA 2013
  • Country
  • BRIA Singapore
  • VRCA United States
  • Employees
  • BRIA N/A
  • VRCA N/A
  • Industry
  • BRIA
  • VRCA Biotechnology: Pharmaceutical Preparations
  • Sector
  • BRIA
  • VRCA Health Care
  • Exchange
  • BRIA NYSE
  • VRCA Nasdaq
  • Market Cap
  • BRIA 47.1M
  • VRCA 43.0M
  • IPO Year
  • BRIA 2024
  • VRCA 2018
  • Fundamental
  • Price
  • BRIA $2.54
  • VRCA $0.53
  • Analyst Decision
  • BRIA
  • VRCA Hold
  • Analyst Count
  • BRIA 0
  • VRCA 5
  • Target Price
  • BRIA N/A
  • VRCA $6.00
  • AVG Volume (30 Days)
  • BRIA 12.0K
  • VRCA 266.5K
  • Earning Date
  • BRIA 06-10-2025
  • VRCA 05-13-2025
  • Dividend Yield
  • BRIA N/A
  • VRCA N/A
  • EPS Growth
  • BRIA N/A
  • VRCA N/A
  • EPS
  • BRIA 92.24
  • VRCA N/A
  • Revenue
  • BRIA $59,695,825.00
  • VRCA $7,179,000.00
  • Revenue This Year
  • BRIA N/A
  • VRCA $127.85
  • Revenue Next Year
  • BRIA N/A
  • VRCA $105.09
  • P/E Ratio
  • BRIA $0.03
  • VRCA N/A
  • Revenue Growth
  • BRIA 8.03
  • VRCA N/A
  • 52 Week Low
  • BRIA $1.78
  • VRCA $0.38
  • 52 Week High
  • BRIA $4.38
  • VRCA $9.36
  • Technical
  • Relative Strength Index (RSI)
  • BRIA N/A
  • VRCA 48.29
  • Support Level
  • BRIA N/A
  • VRCA $0.49
  • Resistance Level
  • BRIA N/A
  • VRCA $0.73
  • Average True Range (ATR)
  • BRIA 0.00
  • VRCA 0.07
  • MACD
  • BRIA 0.00
  • VRCA -0.01
  • Stochastic Oscillator
  • BRIA 0.00
  • VRCA 23.50

About BRIA BRILLIA INC

BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Share on Social Networks: